Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Othman Al-Sawaf, Sandra Robrecht, Matthew S Davids et al. Nov 03, 2025 pp. 2137-2137 10.1182/blood-2025-2137

Abstract Introduction: Treatment options for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma...

Sorafenib enhances anti-leukemia effect via promoting macrophage-NK cell immune crosstalk in FLT3-ITD+ AML patients receiving allo-HSCT

Ruoyang Shao, Peiru Chi, Yuxin Bai et al. Nov 03, 2025 pp. 2308-2308 10.1182/blood-2025-2308

Abstract Sorafenib maintenance therapy has been shown to reduce relapse in FLT3-ITD+ AML patients undergoing allogeneic hematopoietic stem c...

Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study

Amy Alvarenga Tanii, Alana von Glasenapp, Sofía Rivarola et al. Nov 03, 2025 pp. 7145-7145 10.1182/blood-2025-7145

Abstract Background: Data on outcomes and prognostic factors in older adults with Hodgkin lymphoma (HL) from Latin America remain scarce. We...

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Paul Koller, Jose Tinajero, Dat Ngo et al. Nov 03, 2025 pp. 3411-3411 10.1182/blood-2025-3411

Abstract Background Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) have poor outcomes. Allogeneic hematopoietic cell...

Targeting mitophagy through PINK1 splicing sensitizes myeloid malignancies to venetoclax

Xiaolei Liu, Chenchen Li, Justin Wang et al. Nov 03, 2025 pp. 6803-6803 10.1182/blood-2025-6803

Abstract Venetoclax, a BH3 mimetic that impairs mitochondrial function by inhibiting BCL2, has shown remarkable efficacy in the treatment of...

Integrated machine learning, cosmic signatures, and AI-driven genomic profiling of highly heterogeneous blast crisis CML at single patient level resolution: Implication as a versatile risk stratification and precision oncology approach for refractory and relapsed cancers in AI/ML era

Dr Zafar Iqbal, Abdulkareem Al Garni, Sarah Almukhaylid et al. Nov 03, 2025 pp. 3769-3769 10.1182/blood-2025-3769

Abstract Abstract Blast crisis chronic myeloid leukemia (BC-CML) is an aggressive, therapy-resistant phase with poor out...

Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial

Daniel Zheng, Eva Robinson, Yael Flamand et al. Nov 03, 2025 pp. 710-710 10.1182/blood-2025-710

Abstract Introduction: Over 90% of children with acute lymphoblastic leukemia (ALL) will survive their cancer in the context of >2 ye...

Correlates of breakthrough bleeding and emicizumab plasma levels in patients with hemophilia A

Chiamaka Nwachukwu, Christine Robbie, Yue Ming et al. Nov 03, 2025 pp. 2700-2700 10.1182/blood-2025-2700

Abstract Background The efficacy and safety of emicizumab in preventing bleeds in patients with Hemophilia A has been es...

Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review

Yajuan Gao, Kaili Yang, Xuezhu Wang et al. Nov 03, 2025 pp. 7499-7499 10.1182/blood-2025-7499

Abstract Background: Daratumumab has transformed the treatment landscape of AL amyloidosis. However, patients with severe cardiac involvemen...

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Arthur Bobin, Mohamad Mohty, Philippe Moreau et al. Nov 03, 2025 pp. 7566-7566 10.1182/blood-2025-7566

Abstract Introduction: Isatuximab (Isa) given intravenously (IV) with bortezomib, lenalidomide, and dexamethasone (VRd) is associated with a...

Enhancing CAR T cell responses in lymphoma through coadministration of vaccine-educated T cells

Giulia Cheloni, Isabella Saldarriaga, Jessica Liegel et al. Nov 03, 2025 pp. 5893-5893 10.1182/blood-2025-5893

Abstract Background: Chimeric antigen receptor (CAR) T cell therapy has transformed outcomes in advanced B-cell lymphomas, achieving remarka...

Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries

Vivian Oehler, Olga Sala-Torra, Neta Gilderman et al. Nov 03, 2025 pp. 5559-5559 10.1182/blood-2025-5559

Abstract Objectives. Most chronic myeloid leukemia (CML) cases occur in low- and middle- income countries (LMICs) with limited or no access...

Pregnancy outcomes in hereditary and transfusion-associated hemochromatosis: A focused, propensity-matched cohort study using a nationwide inpatient sample

Benedict Amalraj, Mariana Marrero Castillo, Shidestini Martinez Nov 03, 2025 pp. 1124-1124 10.1182/blood-2025-1124

Abstract Introduction: Hemochromatosis, a disorder of iron overload, poses theoretical risks in pregnancy due to iron-mediated oxidative str...

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Rakesh Popat, Oliver Morjaria, Carlyn Tan et al. Nov 03, 2025 pp. 4588-4588 10.1182/blood-2025-4588

Abstract Introduction: Elranatamab (Elra) is a bispecific antibody (BsAb) targeting BCMA that is approved for patients with triple class exp...

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Qingqing Cai, Yi Xia, Qihua Zou et al. Nov 03, 2025 pp. 1906-1906 10.1182/blood-2025-1906

Abstract Background: TP53 mutations, occurring in approximately 20% of diffuse large B-cell lymphoma (DLBCL) cases, are associated with infe...

Inositol hexakisphosphate kinase 1 (IP6K1)-driven tumor polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Young Jun Shim, Alok Khorana, Keith McCrae Nov 03, 2025 pp. 202-202 10.1182/blood-2025-202

Abstract Background: Cancer-associated thrombosis (CAT) is driven by multiple procoagulant mechanisms. Immune checkpoint inhibitors (ICI), w...

Excessive neutrophil extracellular traps formation in sepsis induced acute respiratory distress syndrome: Role of citrullinated histone H3 as a surrogate biomarker and clinical implication

Awirut Charoensappakit, Kritsanawan Sae-khow, Patinya Maneesow et al. Nov 03, 2025 pp. 4760-4760 10.1182/blood-2025-4760

Abstract Background: Despite advancements in therapy, the management of sepsis-induced acute respiratory distress syndrome (ARDS) remains a...

Lymphotoxin alpha (LTA) secretion correlates with gene expression and myeloid malignancy disease state

Kathy McGraw, Beibei Ru, Alain Mina et al. Nov 03, 2025 pp. 2062-2062 10.1182/blood-2025-2062

Abstract Background: Myelodysplastic Syndromes (MDS) are hematopoietic stem cells malignancies whose pathogenesis is, in part, driven by chr...

Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors

Jia Wang, Siyan Niu, Can Liu et al. Nov 03, 2025 pp. 7670-7670 10.1182/blood-2025-7670

Abstract Background: Acute lymphoblastic leukemia (B-ALL) patients who relapse after allogeneic hematopoietic stem cell transplant (allo-HSC...

Machine learning framework for molecular classification of hematologic malignancies using transcriptome data

Karolis Sablauskas, Egija Berga-Švītiņa, Tatjana Kiselova et al. Nov 03, 2025 pp. 2580-2580 10.1182/blood-2025-2580

Abstract BACKGROUND Accurate characterization of hematologic malignancy is a first step in correct and tailored treatment. Tumor whole trans...

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Francesco Mannelli, Giacomo Gianfaldoni, Alfonso Piciocchi et al. Nov 03, 2025 pp. 5243-5243 10.1182/blood-2025-5243

Abstract Background. The aim of intensive induction treatment in acute myeloid leukemia (AML) is the achievement of complete remission (CR)....

Chronic stress promotes myeloid bias in hematopoiesis via the lactobacillus-ila-FoxO1 signaling axis

Hexiao Jia, Xiaodong Guo, Daoxin Ma Nov 03, 2025 pp. 3171-3171 10.1182/blood-2025-3171

Abstract Introduction: Increasing evidence indicates that chronic stress frequently induces alterations in hematopoiesis and promotes inflamm...

Emergency myelopoiesis and monocyte reprogramming underlie immune dysregulation in lymphoma-associated secondary hemophagocytic lymphohistiocytosis

Jeong-Eun Kwak, June-Young Koh, Hye Won Kook et al. Nov 03, 2025 pp. 1210-1210 10.1182/blood-2025-1210

Abstract Malignancy-associated secondary hemophagocytic lymphohistiocytosis (sHLH), particularly in the context of lymphoma, is a life-threa...

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Sarah Kayser, Arnon Nagler, Allain Thibeault Ferhat et al. Nov 03, 2025 pp. 114-114 10.1182/blood-2025-114

Abstract Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for secondary acute myeloid le...

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Alexandra Lovell, Emily Lee, Mikaela McCabe et al. Nov 03, 2025 pp. 5685-5685 10.1182/blood-2025-5685

Abstract Tumor lysis syndrome (TLS) is a known risk with venetoclax (VEN) initiation during treatment for chronic lymphocytic leukemia (CLL)...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page